# Arrowhead Pharmaceuticals (ARWR): value investors who own it

1 value investor held Arrowhead Pharmaceuticals in their Q3 2026 13F, led by Polen Capital Management.

## 13F holders

| Manager | Portfolio | Value | Change | Quarters held |
| --- | --- | --- | --- | --- |
| Polen Capital Management | 0.0% | $539k | New | 1 |

## Directors buying and selling (Form 4, last 12 months)

| Date | Who | Role | Bought or sold | Shares | Value |
| --- | --- | --- | --- | --- | --- |
| 2026-08-18 | PERRY MICHAEL S | Director | Sold | 11600 | $1.0m |
| 2026-08-18 | OLUKOTUN ADEOYE Y | Director | Sold | 2000 | $174k |

Source: SEC filings, via moatshark (https://www.moatshark.com/s/arwr). Values traded and returns are estimates. Not investment advice. Built 2026-10-21.